Future prospects for the use of anticancer drugs in the treatment of NSCLC BRAF mutation or cMET exon 14 skipping mutation are under investigation and clinical trials testing the combination of targeted therapy and immunotherapy are needed. This evidence concerns the gene BRAF and non-small cell lung carcinoma.